Clorox beat market estimates for quarterly net sales on Monday, as U.S. households spent more on disinfectant and other cleaning products due to the Covid-19 pandemic.
Under Armour's second-quarter results were better than the retailer was expecting thanks to an e-commerce boost, but the retailer warned pressures from the coronavirus pandemic will continue to pressure results in the second half of the year.
Sales of Merck's blockbuster cancer drug Keytruda helped offset an 8% decline in revenue to $10.87 billion during second quarter from $11.76 billion from a year earlier.
The company was profitable, reported less operational losses than expected and has already started repaying credits lines it drew down earlier this year to manage through the coronavirus pandemic.
Gilead Sciences' sales fell 10% in the second quarter from a year earlier as the coronavirus pandemic weakened demand for some of its drugs, including some of its core hepatitis treatments.
The company declined to issue guidance for the second quarter in a row, but said on a call with analysts that it expects iPhone supply in the fall to be delayed for a few weeks.